Certara (NASDAQ:CERT) Stock Price Expected to Rise, Barclays Analyst Says

Certara (NASDAQ:CERT) had its price target boosted by stock analysts at Barclays from $9.00 to $12.00 in a research note issued on Friday, Benzinga reports. The firm currently has an “equal weight” rating on the stock. Barclays‘s price objective suggests a potential downside of 0.41% from the company’s current price.

A number of other analysts also recently commented on the stock. UBS Group reiterated a “neutral” rating and issued a $13.00 price objective on shares of Certara in a report on Friday. KeyCorp raised their target price on shares of Certara from $9.00 to $12.00 and gave the stock an “overweight” rating in a research note on Friday, October 16th. Weiss Ratings cut Certara from a “sell (d)” rating to a “sell (d-)” rating in a report on Thursday, October 8th. Finally, TD Cowen upped their price target on Certara from $9.00 to $11.00 and gave the company a “buy” rating in a research report on Tuesday, October 13th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Certara currently has a consensus rating of “Hold” and a consensus target price of $9.92.

Certara Price Performance

Shares of NASDAQ CERT opened at $12.05 on Friday. The firm has a 50-day simple moving average of $9.33 and a 200-day simple moving average of $7.35. The stock has a market capitalization of $1.84 billion, a price-to-earnings ratio of -28.69 and a beta of 1.30. The company has a quick ratio of 2.55, a current ratio of 2.58 and a debt-to-equity ratio of 0.29. Certara has a 52 week low of $4.45 and a 52 week high of $12.61.

Certara (NASDAQ:CERT) last posted its quarterly earnings results on Thursday, November 5th. The company reported $0.09 earnings per share for the quarter, hitting the consensus estimate of $0.09. The firm had revenue of $94.90 million for the quarter, compared to the consensus estimate of $92.01 million. Certara had a negative net margin of 16.14% and a positive return on equity of 3.36%. The company’s revenue for the quarter was down 9.3% on a year-over-year basis. During the same period last year, the firm posted $0.14 earnings per share. Certara has set its FY 2026 guidance at 0.310-0.340 EPS. On average, equities analysts predict that Certara will post 0.21 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. purchased a new stake in shares of Certara in the second quarter valued at about $123,259,000. Dimensional Fund Advisors LP raised its stake in Certara by 2.1% during the first quarter. Dimensional Fund Advisors LP now owns 8,562,508 shares of the company’s stock worth $48,806,000 after purchasing an additional 175,024 shares during the period. Haveli Investment Management LLC purchased a new position in Certara during the second quarter worth about $48,470,000. Jefferies Financial Group Inc. acquired a new position in Certara in the 2nd quarter valued at about $46,446,000. Finally, Bank of America Corp DE boosted its holdings in Certara by 292.2% in the 1st quarter. Bank of America Corp DE now owns 2,042,946 shares of the company’s stock valued at $11,645,000 after purchasing an additional 1,522,034 shares during the last quarter. Institutional investors and hedge funds own 73.96% of the company’s stock.

Key Headlines Impacting Certara

Here are the key news stories impacting Certara this week:

• Positive Sentiment: Certara raised its 2026 revenue outlook to $427.2 million–$431.4 million, well above the cited analyst consensus of $380.9 million. Its EPS guidance of $0.31–$0.34 also met or exceeded the $0.31 consensus midpoint, giving investors a stronger forward outlook. Article: Certara Q3 2026 Earnings Call Highlights
• Positive Sentiment: Third-quarter revenue of $94.9 million topped the $92.0 million consensus, while EPS was reported at $0.09, meeting some estimates and exceeding others. Reports also highlighted double-digit software revenue growth—the first such pace in two years—which helped support a positive share-price reaction after the update. Article: Certara Q3 2026 earnings
• Neutral Sentiment: Barclays raised its price target from $9 to $12 but kept an Equal Weight rating, signaling improved valuation expectations without a bullish call. Article: Barclays price target update
• Negative Sentiment: UBS downgraded CERT from Buy to Neutral, though its $13 price target remains above the price cited in the report. The downgrade may restrain enthusiasm after the stock’s recent rally. Article: UBS downgrades Certara

About Certara

Certara is a global provider of software and services that support drug development and regulatory approval. The company helps biopharmaceutical and pharmaceutical organizations use quantitative methods, modeling and simulation, and regulatory science to improve decisions throughout the development process.

Its software portfolio includes platforms for pharmacometric modeling and simulation, clinical trial design and analysis, pharmacology and safety assessment, data visualization, and regulatory submission management.